Specialty Chemicals company Godavari Biorefineries announced Q2FY26 results Total Income: Rs 434.3 crore against Rs 322.1 crore during Q2FY25. EBITDA: Rs -4.4 crore against Rs -31.5 crore during Q2FY25. EBITDA Margin: -1.0% for Q2FY26. PBT: Rs -56.9 crore against Rs -64.1 crore during Q2FY25. PAT: Rs -41.6 crore against Rs -75.0 crore during Q2FY25. PAT Margin: -9.6% for Q2FY26. Shri Samir Somaiya, CMD, said: ““Q2FY26 has shown early signs of recovery for the company. We achieved 34% growth in revenue from operations, and significantly narrowed EBITDA losses to Rs 4.4 crore, down from Rs 31.5 crore in the same quarter last year. Segment performance continues to validate our direction. Bio-based chemicals segment delivered 60% EBITDA growth, while Ethanol segment EBITDA turned positive at Rs 4.7 crore, compared to a loss of Rs 2.9 crore last year. This improvement reflects the impact of our strategic focus on bio-based specialty chemicals and the restoration of the Ethanol Blending Programme. As part of our progress in drug discovery ,the Clinical Study Report of our novel anti-cancer molecule reflecting the successful conclusion of our safety trials has been received. This will now enable us to prepare the application for the next phase of drug discovery – preliminary efficacy trials. Also, a European patent application titled “COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH” has been granted for processing under our Anti-Cancer Research segment, strengthening our pipeline in advanced therapeutics. Our 200 KLPD fungible grain/maize distillery is targeted for commissioning in Q4FY26. This facility will enable us to capitalise on diversified feedstock, particularly as grain/maize based ethanol gain traction, thereby enhancing feedstock flexibility and margin resilience. In a major step toward sustainability, Godavari Biorefineries, in collaboration with ICT Mumbai, has launched a pilot CO?-to-DME project. This is a revolutionary breakthrough technology in climate action. This revolutionary technology converts industrial CO2 emissions directly into Dimethyl Ether (DME) — a low-emission, eco-friendly energy carrier. Dimethyl ether (DME) is a clean-burning fuel that can effectively replace conventional energy sources such as liquefied petroleum gas (LPG) and diesel, contributing to reduced emissions, improved environmental performance and decarbonisation. The initiative reflects our commitment to clean energy and offering sustainable solutions. We are progressing as planned. Our efforts to mitigate seasonality risks are visible in the increased focus on high-potential bio-based specialty chemicals, ongoing debottlenecking, and strategic investments in multi-feedstock ethanol capacity. On the R&D; front, we continue to drive long-term growth through scientific innovation and sustainability-led solutions. With these initiatives, we remain confident in our ability to create sustainable value for all stakeholders.” Result PDF
Specialty Chemicals company Godavari Biorefineries announced Q1FY26 results Total Income: Rs 534.0 crore compared to Rs 525.3 crore during Q1FY25. EBITDA: Rs 6.5 crore compared to Rs -9.5 crore during Q1FY25. EBITDA Margin: 1.2% for Q1FY26. PBT: Rs -22.3 crore compared to Rs -41.6 crore during Q1FY25. PAT: Rs -16.0 crore compared to Rs -26.1 crore during Q1FY25. PAT Margin: -3.0% for Q1FY26. Shri Samir Somaiya, CMD said: “Q1FY26 has been a quarter of resilience and progress for our Company. Despite the seasonality inherent in some of our segments, we delivered an improved performance with revenue from operations at Rs 533.2 crore, an improvement over the same quarter last year, and achieved an EBITDA of Rs 6.5 crore. Our BioBased Chemicals segment recorded a strong 43% YoY growth in EBITDA. On the ethanol front, from Sugar Season 2024-25 the restoration of the Ethanol Blending Program from Juice/Syrup helped us to produce more Ethanol from B heavy molasses. Our upcoming grain-based ethanol capacity will add a new growth lever. We are also proud to share significant progress in our Drug Discovery efforts. European patent for our novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. Safety trials for the same molecule have been concluded without any dose limiting toxicity (DLT). Additionally, we have been granted a patent by the China National Intellectual Property Administration (CNIPA) for another novel anti-cancer molecule – HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a new class of compounds that have demonstrated strong inhibitory effects on cancer and cancer stem cells in vitro. These compounds have shown significant efficacy against multiple cancer types, including breast and prostate cancer. Looking ahead, our strategic focus remains on strengthening the bio-based chemicals segment through ongoing debottlenecking and the development of Bio-based specialty chemicals. In parallel, we are enhancing our multi-feedstock ethanol capabilities and investing in continuous research and development to drive long-term growth and innovation. With these initiatives, we remain confident of creating sustainable value for all stakeholders.” Result PDF
Specialty Chemicals company Godavari Biorefineries announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations stood at Rs 579.5 crore as against Rs 615.2 crore, a decrease of 5.79% YoY. EBITDA* stood at Rs 121.7 crore as against Rs 124.4 crore, a decrease of 2.17% YoY. EBITDA Margins stood at 21.0% as against 20.2%, a growth of 0.8 percentage points YoY. PAT (excl. one time impact of Deferred Tax) stood at Rs 96.4 crore as against Rs 65.2 crore, a growth of 47.85% YoY. PAT Margins stood at 16.6% as against 10.6%, a growth of 6.0 percentage points YoY. FY25 Financial Highlights: Revenue from Operations stood at Rs 1,870.3 crore as against Rs 1,686.7 crore, a growth of 10.89% YoY. EBITDA* stood at Rs 120.3 crore as against Rs 147.9 crore, a decrease of 18.79% YoY. EBITDA Margins stood at 6.4% as against 8.8%, a decrease of 2.4 percentage points YoY. PAT (excl. one time impact of Deferred Tax) stood at Rs 1.1 crore as against Rs 12.3 crore, a decrease of 91.06% YoY. PAT Margins stood at 0.1% as against 0.7%, a decrease of 0.6 percentage points YoY. Commenting on the Results, Shri Samir Somaiya, CMD said, “FY25 was a defining year for Godavari Biorefineries, showcasing our agility, disciplined execution, and strategic progress. Our Bio-based Chemicals segment delivered over 2x growth in EBITDA, propelled by our shift toward high-value, sustainable solutions and enhanced operational efficiencies. We also achieved a record cane crushing of 24.65 lakh tonnes for sugar season 2024-25 at our Sameerwadi facility. The restoration of the ethanol blending programme using sugarcane juice enabled us to better utilize our ethanol capacity during the crushing season Looking ahead, our 200 KLPD grain/maize distillery is progressing as planned and is expected to be commissioned in Q4FY26. We are also exploring multi-feedstock options for greater flexibility, while undertaking debottlenecking and expansion initiatives focused on specialty products. FY25 has laid a solid foundation for future growth, and we remain committed to delivering value through innovation, sustainability, and disciplined growth.” Result PDF